# Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

Source: https://onco.cc/trials/nct06577987/  
OnCo record `nct06577987` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CID-078 run by Circle Pharma, active and no longer recruiting.

## Summary

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies is a phase 1 interventional study registered as NCT06577987 by Circle Pharma, with 220 participants planned, started 2024-08-14. Conditions recorded: Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer, Lung Cancer, Triple Negative Breast Cancer, Breast Neoplasms, Neuroendocrine Tumors, Neuroendocrine Carcinoma and RB1 Gene Mutation. Interventions recorded: CID-078 Monotherapy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06577987
- Phase: 1
- Setting: A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients With Advanced Solid Tumor Malignancies
- Sponsor: Circle Pharma
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT06577987: https://clinicaltrials.gov/study/NCT06577987

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Small cell neuroendocrine carcinoma of the cervix](https://onco.cc/cancers/cervical-small-cell-neuroendocrine-carcinoma/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [CID-078](https://onco.cc/drugs/cid-078/)
- companies: [Circle Pharma](https://onco.cc/companies/circle-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06577987.json